To hear about similar clinical trials, please enter your email below
Trial Title:
Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer
NCT ID:
NCT05991180
Condition:
Extensive-stage Small-cell Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
This is a descriptive observational study, in which data are collected in an
epidemiological fashion and prospective. This study does not intend to intervene the
current medical practice of the recruited patients.
Criteria for eligibility:
Study pop:
Extensive Stage Small Cell Lung Cancer
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Patients must be ≥18 years.
- Provision of fully informed consent prior to any study specific procedures.
- Patients with extensive stage SCLC diagnosed by pathology (as staged by the American
Veterans Lung Cancer Association (VALG)), who do not have an imaging response during
first-line treatment with PD-(L)1 inhibitors, or who progress after imaging
reactions on first-line therapy (the most recent regimen prior to enrollment must
contain PD-(L)1 inhibitors).
- According to the RECIST 1.1 standard, the patient must have at least one measurable
lesion.
Exclusion Criteria:
- None
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
Hunan Cancer hospital
Address:
City:
Changsha
Country:
China
Status:
Recruiting
Contact:
Last name:
Yongchang Zhang, MD
Phone:
+86 731 89762321
Email:
zhangyongchang@csu.edu.cn
Start date:
December 25, 2023
Completion date:
December 31, 2025
Lead sponsor:
Agency:
Hunan Province Tumor Hospital
Agency class:
Other
Source:
Hunan Province Tumor Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05991180
